Carlo Visco, MD

Carlo Visco, MD, is an associate professor of hematology in the Department of Medicine, coordinator of the Lymphoma Team in the Hematology and Bone Marrow Transplant Unit in the Section of Biomedical Innovation in the Department of Engineering for Innovative Medicine at the University of Verona

Articles

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

November 13th 2025

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Dr Visco on Unmet Needs for Patients With Mantle Cell Lymphoma

November 6th 2025

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.

Dr Visco on the Role of RBAC Dose Reductions for High-Risk MCL

October 30th 2025

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Dr Visco on the Efficacy and Safety of Venetoclax Plus RBAC in High-Risk MCL

October 23rd 2025

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Dr Visco on the Design of the FIL_V-RBAC Trial of RBAC Plus Venetoclax in High-Risk MCL

October 16th 2025

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCL

October 15th 2020

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Dr. Visco on Next Steps for the MANTLE-FIRST Trial in Relapsed/Refractory MCL

September 17th 2020

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. Visco on the Utility of Bendamustine in MCL

September 15th 2020

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Dr. Visco on the Utility of Cytarabine in MCL

September 10th 2020

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.